Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

An exclusive interview with Pfizer’s Wayne Simmons on reshaping customer experience by listening to those interacting with ...

In 2024, Pfizer generated free cash flow of $9.8 billion, which was more than the $9.5 billion it paid out in dividends. 3. The company looks to still be in acquisition mode Pfizer previously told ...

After many years of struggling to bring out important new drugs, Pfizer is now launching several potential blockbusters in cancer and immunology. The company's 2023 acquisition of Seagen has also ...